CRYSTALLINE FORM HAVING SPECIFIC CRYSTAL HABIT AND PHARMACEUTICAL COMPOSITIONCONTAINING THIS CRYSTALLINE FORM AS ACTIVE INGREDIENT

摘要

Means for improving the solubility of luliconazole is provided. A crystal of luliconazole represented by the following formula is provided, wherein the crystal has such a crystal habit that (01 1) plane is a specific crystal g rowth plane. The crystal is characterized in that Lon) with respect to a sum total of I(o0i), I(ioo), I(io-i), I(oii), I(iio), I(ii-i), I(io-2), I(ii-2), 1(020), I(02i), Ipo-2), I(i2i), I(ois), I(ii- s), and I(22i) is not less than 25%, provided that integrated intensities of diffraction peaks, which correspond to the (001), (100), (10- 1), (011), (110), (11-1), (10-2), (11-2), (020), (021), (20-2), (121), (013), (11-3), and (221) planes, are designated as I(0oi), I(ioo), I(io- i), I(oii), I(iio), I(ii-i), I(io-2), 1(11-2), 1(020), 1(021), 1(20-2), 1(121), 1(013), 1(11-3), and 1(221) respectively in relation to the diffraction peaks detected in a range of 20= 5 to 35� in a powder X-ray diffractometry using CuKa radiation.